

Members

Member States

Czech Republic

- **Pavel Hroboň** | Former Deputy Minister | Ministry of Health

France

- **Eric Abadie** | Direction Générale | Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)
- **Noël Renaudin** | President | Economic Committee for Health Products (CEPS)

Germany

- **Rainer Hess** | Impartial Chairman | Federal Joint Committee (G-BA)
- **Wolfgang Schmeinck** | Beauftragter des Vorstandes | BKK Landesverband Nordrhein-Westfalen

Netherlands

- **Mike Leers** | Advisor - Board of Commissioners | CZ Healthcare Insurance Group
- **Martin van Rijn** | CEO | PGGM

United Kingdom

- **Mike Farrar CBE** | Chief Executive | National Health Service - North West
- **Sir Michael Rawlins** | Chairman | National Institute for Health & Clinical Excellence (NICE)
- **Professor Sir Mike Richards CBE** | National Clinical Director for Cancer & End of Life Care | St Thomas' Hospital

Pharmaceutical Innovators

- **Eddie Gray** | President, Pharmaceuticals Europe | GlaxoSmithKline
- **David Norton** | Company Group Chairman - Global Pharmaceuticals | Johnson & Johnson
- **Ulf Säther** | Regional Vice President, Europe | AstraZeneca

Other Key Constituents

- **David Byrne** | Former EU Commissioner, Health and Consumer Protection
- **Thomas Lönngren** | Executive Director | European Medicines Agency (EMA)
- **Anders Olauson** | President | European Patients' Forum
- **Sophia Tickell** | Executive Director | SustainAbility & Director | Pharma Futures

Breast Cancer

Medical subject matter experts

- Jonas Bergh, Karolinska Institute, Sweden
- PierFranco Conte, Universitaria di Modena, Italy
- Jindřich Fínek, University Hospital Plzen, Czech Republic
- Luca Gianni, University of Milan, Italy
- Anthony Howell, The Christie NHS Foundation Trust, UK
- Christian Jackisch, Klinikum Offenbach GmbH, Germany
- David Khayat, Pitié-Salpêtrière Hospital, France
- Jan Lubiński, Pomeranian Medical University, Poland
- Larry Norton, Memorial Sloan-Kettering Cancer Center, USA
- John Robertson, University of Nottingham, UK
- Karol Sikora, CancerPartners UK, UK
- Michael Untch, HELIOS Klinikum, Germany

Payers, regulators, health economists, and advisors

- Johannes Bruns, Deutsche Krebsgesellschaft, Germany
- Karl Claxton, University of York, UK
- Pierre Démolis, Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS)
- Harald Enzmann, Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Germany
- Pavel Hroboň, formerly Ministry of Health, Czech Republic
- Bengt Jönsson, Stockholm School of Economics, Sweden
- Bertil Jonsson, Medical Products Agency, Sweden
- Sören Olofsson, Region Skåne, Sweden

Patient representatives

- Els Borst-Eilers, Dutch Federation of Cancer Patients, The Netherlands
- Susan Knox, EUROPA DONNA, European Breast Cancer Coalition (OBSERVER)

Industry representatives

- Jim Baker, Johnson & Johnson
- Alan Barge, AstraZeneca
- Paolo Paoletti, GlaxoSmithKline

Diabetes

Medical subject matter experts

- Amanda Adler, Institute of Metabolic Science, Cambridge, UK
- Jean-François Bergmann, Hôpital Lariboisière Paris, France
- Christian Berne, Uppsala University, Sweden
- Bernard Charbonnel, University of Nantes, France
- Ele Ferrannini, University of Pisa School of Medicine, Italy
- Vivian Fonseca, Tulane University Medical Center, USA
- Philip Home, Newcastle University, UK
- Harald Klein, Ruhr-Universität Bochum, Germany
- Mohan Kumar, NHS North Western Deanery, UK
- Andrew Morris, University of Dundee, UK
- Eberhard Standl, Munich Diabetes Research Institute, Germany

Payers, regulators, health economists and advisors

- Andrew Briggs, University of Glasgow, UK
- Hans-Georg Eichler, European Medicines Agency (EMA)
- Peter Kolominsky-Rabas, University of Erlangen-Nuremberg, Germany
- Félix Lobo-Aleu, Universidad Carlos III, Spain
- Noël Renaudin, Economic Committee for Health Products (CEPS), France
- Michael Schlander, Institute for Innovation and Valuation in Health Care, Germany
- Sjaak Verduijn, CZ Insurance, The Netherlands

Patient representatives

- Maarten Ploeg, Dutch Diabetes Association, The Netherlands

Industry representatives

- Martin Fitchet, Johnson & Johnson
- Gunnar Olsson, AstraZeneca
- Carlo Russo, GlaxoSmithKline